Replies to post #154712 on Biotech Values

[xrymd]

Uveitis is a full-fledged phase-3 program including three trials; the program is partnered with Servier

I thought that uveitis was a small niche market. The company was always talking about Diabetes and the past results were not great. Now they seem to be taking a shot at CV. Seems like a stretch for them.